这句话怎么看不懂了

The most recent randomized controlled trials of ECMO and ECCO2R for ARDS also found no mortality benefit compared to well-established protocolized LPV management used in the Express and ARDSNet trials. However, the results of the“EOLIA” trial were intriguing given the clear trend towards improved mortality favoring ECMO (35% vs. 46%, P=0.09) and significant improvement when analyzed according to treatment failure (ie. mortality in the ECMO arm vs. mortality and crossover to ECMO therapy in the LPV arm): 35% vs. 58%, P<0.001.

与Express和ARDSNet研究中使用的成熟的程序化LPV管理相比，最新的ECMO和ECCO₂R治疗ARDS的随机对照研究也发现未有死亡率方面的获益。然而，考虑到根据治疗失败进行分析时(即ECMO组的死亡率与LPV组交叉ECMO治疗后的死亡率相比:35%比58%，P<0.001）。死亡率明显有利于ECMO（35%对46%，P=0.09）治疗，“EOLIA”的研究结果耐人寻味。

这句话怎么看不懂了，一个死亡率P<0.001，还有一个死亡率P=0.09，

(ie. mortality in the ECMO arm vs. mortality and crossover to ECMO therapy in the LPV arm

这里的比较又看不懂了，感觉像3个比较，但是只有2个数据，crossover 啥意思

这篇参考文献找不到，大家能帮我下载一下吗？

Combes A, Hajage D, Capellier G, Demoule A, Lavoue S, Guervilly C, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med 2018;378(21):1965-1975.